Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, announces the sale of SSI Strategy (“SSI”), a trusted strategic consulting partner to biotech innovators, to Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle. Today, SSI provides a fully integrated offering to address medical, clinical, regulatory, safety and organizational challenges at all stages of drug development. The company serves a diverse and growing biotech client base from early development through launch across a comprehensive range of scientific functions.
Read the full article: Amulet Capital Announces Sale of SSI Strategy to Clinigen //
Source: https://www.businesswire.com/news/home/20250928613145/en/Amulet-Capital-Announces-Sale-of-SSI-Strategy-to-Clinigen